India Pharma and Healthcare Sector Report 2025-2026

India's pharmaceutical and healthcare sector is world-renowned. India's reputation as the "pharmacy of the world" was earned from its extensive production of generic medications and vaccines. For instance, Serum Institute of India, a vaccine producer, was instrumental in developing vaccines to combat the COVID-19 pandemic. Meanwhile, India's hospitals are accommodating increasing medical tourists due to their reputation for providing high-quality, yet affordable, healthcare. Indian patients can increasingly access modern healthcare, owing primarily to increased participation in Ayushman Bharat, the government-funded public health insurance programme. Despite these encouraging signs, India's pharmaceutical and healthcare sector faces daunting challenges. India has limited healthcare infrastructure due to decades of underfunding and the ongoing migration of competent medical professionals to higher-paying countries. The Indian healthcare system also depends on imported pharmaceutical raw materials, medical devices, and patented medications due to its limited domestic production capacity.

This report provides a complete and detailed analysis of the "Pharmaceuticals production" sector for India. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Pharmaceuticals production" sector in India
• Crystallise the forces both driving and restraining this sector in India
• Ascertain India’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in India.
• Build a clear picture of trends, output and consumption for specific sub-sectors